| ⚠ Research Use Only (RUO) — For laboratory and research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. This product is not FDA-approved. For use by qualified researchers only. |
Researchers combine CJC-1295 and Ipamorelin because the two peptides hit different growth hormone pathways at the same time. CJC-1295 triggers a sustained GH pulse. Ipamorelin triggers an immediate one. Together, they produce a stronger, longer GH response than either compound achieves alone.
This guide covers the mechanism of each peptide, why researchers stack them, the published synergy data, storage requirements, and how to source verified research-grade blend.
What Is CJC-1295?
CJC-1295 (also called Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH). It contains 29 amino acids with four substitutions at positions 2, 8, 15, and 27. Those substitutions increase receptor binding strength and resistance to enzymatic degradation.
CJC-1295 binds to GHRH receptors in the pituitary gland. It stimulates somatotroph cells to produce and release growth hormone in a sustained, pulsatile pattern. A clinical study published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006) demonstrated dose-dependent GH and IGF-1 increases lasting up to 28 days with no serious adverse events.
CJC-1295 (No DAC) vs. CJC-1295 (with DAC)
The No DAC version lacks the Drug Affinity Complex. A lysine modification that binds albumin and extends half-life to 6–8 days. No DAC provides a shorter, more physiologic pulse. Researchers studying pulsatile GH patterns use No DAC. Researchers studying sustained baseline elevation use the DAC version.
What Is Ipamorelin?
Ipamorelin (NNC 26-0161) is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It acts as a selective growth hormone secretagogue (GHS) by mimicking ghrelin and binding the GHS-R1a receptor in the pituitary gland.
Ipamorelin triggers a fast, clean GH pulse. It does not elevate cortisol, prolactin, ACTH, FSH, LH, or TSH. This receptor selectivity makes it unique among GHRPs other peptides in its class frequently produce cortisol and prolactin elevation as side effects. Ipamorelin avoids this entirely.
A study in the European Journal of Endocrinology (Raun et al., 1998) identified Ipamorelin as the first selective growth hormone secretagogue, confirming GH-specific release without stimulating other pituitary hormones.
Why Do Researchers Combine Them?
CJC-1295 and Ipamorelin activate two separate receptor systems in the pituitary gland:
| Peptide | Receptor Target | Mechanism | Effect |
| CJC-1295 (No DAC) | GHRH Receptor | Gs protein → cAMP → PKA → GH gene transcription | Sustained GH pulse amplitude |
| Ipamorelin | GHS-R1a (Ghrelin receptor) | Gq protein → intracellular calcium → PKC | Rapid GH pulse frequency |
These two pathways operate through entirely different intracellular signaling cascades. When researchers activate both simultaneously, the combination amplifies GH release beyond what either compound achieves alone. Published research shows combined use produces a 3–5 fold increase in GH output compared to single-peptide protocols.
The timing is complementary: Ipamorelin delivers peak GH release within two hours of administration. As Ipamorelin activity wanes, CJC-1295 sustains elevated GH output for an extended window.
What Do Researchers Study With This Blend?
Active research applications include:
- Growth hormone pulsatility studies: Dual-pathway activation models for studying natural GH rhythm
- Body composition research: Lean mass preservation vs. fat oxidation in GH-deficient models
- Bone metabolism: Ipamorelin increases longitudinal bone growth in rat models (Johansen et al., 1999)
- Muscle tissue repair: IGF-1 elevation downstream of GH release supports protein synthesis studies
- Sleep architecture: GH secretion peaks during slow-wave sleep; researchers study this correlation
- Collagen synthesis: GH-driven collagen production in skin and connective tissue models
- Metabolic signaling: Lipolysis and glucose uptake regulation under elevated GH conditions
- Cognitive function: IGF-1 receptor activity in neural tissue research
Purity and Formulation Standards
Research-grade CJC-1295 Ipamorelin blend ships in lyophilized (freeze-dried) form. Standard formulation is a 1:1 ratio — 5mg CJC-1295 No DAC combined with 5mg Ipamorelin in a single 10mg vial.
Minimum purity standards for research use:
- HPLC purity: ≥98% (confirmed per peptide, not total blend)
- Mass spectrometry: Molecular weight confirmation for both compounds
- Endotoxin testing: ≤1 EU/mg
- Batch-specific COA from an independent third-party laboratory
Always request a COA with a batch number that matches the vial label. Never accept a generic or undated certificate.
Buy CJC-1295 Ipamorelin Blend | Hotspan
Hotspan supplies research-grade CJC-1295 Ipamorelin blend with third-party verified COAs. Every batch undergoes HPLC purity confirmation before shipping. Each vial ships with a batch-matched certificate from an independent laboratory, so researchers can verify compound identity and purity before beginning any protocol.
| Vial Size | Contents | Price |
| 10mg | CJC-1295 No DAC / Ipamorelin (5mg : 5mg) | $79 |
Order now at https://hotspan.com/product/cjc-1295-ipamorelin/
| Looking for physician-supervised GH optimization protocols? Hotspan’s clinical division, Ola Digital Health, offers prescription-based longevity protocols supervised by licensed physicians. Explore Hotspan → hotspan.com |
Storage and Handling Protocol
Lyophilized (unopened): Store at -20°C. Protect from light and humidity. Shelf life: 24 months when stored correctly.
Reconstitution: Add bacteriostatic water slowly along the inner wall of the vial. Do not inject water directly onto the powder. Gently swirl, do not shake. Standard reconstitution uses 2–3 mL bacteriostatic water per 10mg vial.
After reconstitution: Refrigerate at 2–8°C. Use within 28 days. Avoid freeze-thaw cycles. Each cycle degrades peptide integrity.
Frequently Asked Questions
What is the CJC-1295 Ipamorelin blend used for in research?
Researchers use the blend to study dual-pathway growth hormone activation. It enables simultaneous study of GHRH receptor signaling (via CJC-1295) and ghrelin receptor signaling (via Ipamorelin) in a single protocol.
Does Ipamorelin raise cortisol in research models?
No. Ipamorelin selectively stimulates GH release without affecting cortisol, ACTH, prolactin, or other pituitary hormones. This selectivity distinguishes it from other GHRPs in the same class.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC binds albumin and extends half-life to 6–8 days, producing sustained GH elevation. CJC-1295 No DAC has a shorter half-life and produces a more physiologic pulsatile release. Research blends typically use No DAC for pulsatility modeling.
What purity should the blend have?
Each component requires ≥98% HPLC purity confirmed individually, plus mass spectrometry verification and a batch-matched third-party COA.
How do researchers store the reconstituted blend?
Refrigerate at 2–8°C after reconstitution. Use within 28 days. Avoid repeated freeze-thaw cycles.
Is the CJC-1295 Ipamorelin blend FDA-approved?
No. Both peptides are non-FDA-approved research compounds. They are available for laboratory and research use only under a research-use-only (RUO) designation and are not for human consumption.
What ratio of CJC-1295 to Ipamorelin do research blends use?
Standard research blends use a 1:1 ratio — 5mg CJC-1295 No DAC and 5mg Ipamorelin in a 10mg total vial. Some vendors offer 12mg:6mg ratios depending on the protocol design.
Who is this product intended for?
Licensed researchers, academic institutions, and laboratory professionals. This product is not for personal use and is sold exclusively for in vitro and preclinical research applications.
Conclusion
The CJC-1295 Ipamorelin blend activates two independent GH secretion pathways simultaneously: GHRH receptor signaling through CJC-1295 and ghrelin receptor signaling through Ipamorelin. This dual activation produces synergistic GH release that neither compound achieves alone. Researchers use the blend to study growth hormone pulsatility, lean mass dynamics, bone metabolism, collagen synthesis, and metabolic signaling.
At Hotspan, sourcing integrity is not a checkbox; it is the foundation of every research product we supply. Our mission is to double lifespan, healthspan, and hotspan. That starts with compounds you can trust: every vial third-party verified, every batch traceable, every COA batch-matched before it ships.
Order research-grade CJC-1295 Ipamorelin blend at hotspan. For physician-supervised protocols, visit hotspan.com.